



US009408851B2

(12) **United States Patent**
Borthwick et al.

(10) **Patent No.:** **US 9,408,851 B2**

(45) **Date of Patent:** ***Aug. 9, 2016**

(54) **COMPOUNDS**

(71) Applicant: **Glaxo Group Limited**, Brentford, Middlesex (GB)

(72) Inventors: **Alan David Borthwick**, Stevenage (GB); **Deirdre Mary Bernadette Hickey**, Stevenage (GB); **John Liddle**, Stevenage (GB); **Andrew McMurtrie Mason**, Stevenage (GB)

(73) Assignee: **Glaxo Group Limited**, Brentford, Middlesex (GB)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/881,322**

(22) Filed: **Oct. 13, 2015**

(65) **Prior Publication Data**

US 2016/0030442 A1 Feb. 4, 2016

Related U.S. Application Data

(63) Continuation of application No. 14/623,098, filed on Feb. 16, 2015, now abandoned, which is a continuation of application No. 14/261,994, filed on Apr. 25, 2014, now abandoned, which is a continuation of application No. 13/897,853, filed on May 20, 2013, now Pat. No. 8,742,099, which is a continuation of application No. 13/451,196, filed on Apr. 19, 2012, now abandoned, which is a continuation of application No. 13/035,366, filed on Feb. 25, 2011, now Pat. No. 8,202,864, which is a continuation of application No. 12/850,386, filed on Aug. 4, 2010, now Pat. No. 7,919,492, which is a continuation of application No. 12/480,182, filed on Jun. 8, 2009, now abandoned, which is a continuation of application No. 11/630,179, filed as application No. PCT/EP2005/006760 on Jun. 21, 2005, now Pat. No. 7,550,462.

(30) **Foreign Application Priority Data**

Jun. 23, 2004 (GB) 0414093.5

(51) **Int. Cl.**

A61K 31/5377 (2006.01)

C07D 413/14 (2006.01)

C07D 401/06 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/5377** (2013.01); **C07D 401/06** (2013.01); **C07D 413/14** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,596,819 A	6/1986	Nicolaides et al.
5,464,788 A	11/1995	Bock et al.
5,817,751 A	10/1998	Szardenings et al.
7,550,462 B2	6/2009	Borthwick et al.
7,919,492 B2	4/2011	Borthwick et al.
8,202,864 B2	6/2012	Borthwick et al.
8,742,099 B2	6/2014	Borthwick et al.
2005/0148572 A1	7/2005	Borthwick et al.
2007/0149524 A1	6/2007	Liddle
2007/0185162 A1	8/2007	Borthwick et al.
2007/0208031 A1	9/2007	Borthwick et al.

FOREIGN PATENT DOCUMENTS

DE	3830096	1/2004
GB	2326639	12/1998
WO	WO 99/37304 A1	7/1999
WO	WO 99/38844 A1	8/1999
WO	WO 99/47549 A1	9/1999
WO	WO 03/053443 A1	7/2003
WO	WO 2005/000311 A1	1/2005
WO	WO 2005/000840 A1	1/2005
WO	WO 2006/000400 A1	1/2006
WO	WO 2006/000759 A1	6/2006
WO	WO 2006/067462 A1	6/2006

OTHER PUBLICATIONS

Akerlund; Prog. Brain. Res.; 2002; vol. 139; pp. 359-365.
Assinder et al.; Effects of Steroids on Oxytocin Secretion by the Human Prostate In Vitro; International Journal of Andrology; 2004; vol. 27; pp. 12-18.
Banker et al.; Modern Pharmaceuticals, 3rd Ed.; 1996; p. 596.


(Continued)

Primary Examiner — Emily Bernhardt

(74) *Attorney, Agent, or Firm* — Robert H. Brink

(57) **ABSTRACT**

Compounds of formula (I)



wherein R₁ is 2-indanyl, R₂ is 1-methylpropyl, R₃ is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R₄ represents methyl and R₅ represents hydrogen or methyl or, R₄ and R₅ together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.

2 Claims, No Drawings